A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/00 (2006.01) A61K 31/593 (2006.01) A61K 47/10 (2006.01)
Patent
CA 2651283
Pharmaceutical pulmonary compositions, methods of delivery to the lungs of a human and methods of treatment thereof. Pharmaceutical formulations including 1.alpha.,25-dihydroxyvitamin D3, an alcohol such as ethanol, and a polyol such as propylene glycol. Another pharmaceutical pulmonary formulation includes 1.alpha.,25-dihydroxyvitamin D3 and dry bulking powder, which is used in a dry powder inhaler. Another pharmaceutical formulation includes 1.alpha.,25-dihydroxyvitamin D3 and an aerosol propellant, which is used in a metered dose inhaler. The pharmaceutical pulmonary formulations may include a second active pharmaceutical ingredient such as calcitonin or a N-terminal peptide fragment of parathyroid hormone consisting of the first (34) to (38) amino acids of SEQ ID No. 1. Pulmonary delivery of the formulations efficaciously increase serum calcium levels in mammals, manage hypocalcemia, treat calcium metabolic disorder and reduce elevated parathyroid hormone levels.
L'invention concerne des compositions pharmaceutiques pulmonaires, des procédés d'administration pulmonaire chez un patient humain, et des méthodes de traitement associées, des formulations pharmaceutiques contenant de la 1a,25-dihydroxyvitamine D<SUB>3</SUB>, un alcool tel que l'éthanol et un polyol tel que le propylène glycol, une autre formulation pharmaceutique pulmonaire comprenant la 1a,25-dihydroxyvitamine D<SUB>3</SUB> et une poudre sèche de diluant, qui est utilisée dans un inhalateur de poudre sèche; une autre formulation pharmaceutique comprenant la 1a,25-dihydroxyvitamine D<SUB>3 </SUB>et un gaz propulseur aérosol, qui est utilisée dans un aérosol-doseur. Les formulations pharmaceutiques pulmonaires peuvent comprendre un second principe actif pharmaceutique tel que la calcitonine ou un fragment peptidique N-terminal de la parathormone, constitué des premiers (34 à 38) acides aminés de la SEQ. ID No. 1. L'administration pulmonaire de ces formulations permet d'augmenter efficacement les taux de calcium sérique chez des mammifères, de réguler l'hypocalcémie, de traiter un trouble métabolique du calcium et de réduire des taux élevés de la parathormone.
Clagett-Dame Margaret
Deluca Hector F.
Plum Lora A.
Rivera-Bermudez Moises A.
Smart & Biggar
Wisconsin Alumni Research Foundation
LandOfFree
Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2017860